At MiMARK we envision the gynecological fluid as the next liquid biopsy in gynecology, to develop pain-free, accurate, and accessible diagnostic solutions.

Our 1st product, WomEC, is an IVD assay for diagnosing Endometrial Cancer (EC). Every year, 70M women worldwide presenting with abnormal uterine bleeding will undergo a multistep and inaccurate diagnostic journey.

EC diagnosis failure has dramatic consequences: invasive procedures are needed, and the patient has the risk of receiving sub-optimal surgery.

With WomEC we will have 99% diagnosis without invasive procedures and guide optimal surgery. WomEC has been verified in 5 independent clinical retrospective studies involving +600 patients.

The company was incorporated in January 2021. MiMARK was the winning company in the EIT Health Wild Card competition and was awarded 1.5M€. As of today, the company has nearly gained 5M€ in competitive national and European funding (including the competitive European grant, EIC Accelerator). In addition, the company closed a successful 1.7 million EUR funding seed round.

Keywords: Pharmaceuticals and Biotechnology, Cancer Diagnostics, Cancer Treatment, Gynaecological Treatment, Gynecological Care, Health Tech, Pathological Examination, Women's Health.